HK1209054A1 - Laquinimod formulations without alkalizing agent - Google Patents

Laquinimod formulations without alkalizing agent

Info

Publication number
HK1209054A1
HK1209054A1 HK15109818.4A HK15109818A HK1209054A1 HK 1209054 A1 HK1209054 A1 HK 1209054A1 HK 15109818 A HK15109818 A HK 15109818A HK 1209054 A1 HK1209054 A1 HK 1209054A1
Authority
HK
Hong Kong
Prior art keywords
alkalizing agent
laquinimod
formulations
laquinimod formulations
alkalizing
Prior art date
Application number
HK15109818.4A
Other languages
English (en)
Chinese (zh)
Inventor
Gadi Sarfatti
Ioana Lovinger
Danit Licht
Muhammad Safadi
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of HK1209054A1 publication Critical patent/HK1209054A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK15109818.4A 2012-07-11 2015-10-08 Laquinimod formulations without alkalizing agent HK1209054A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261670268P 2012-07-11 2012-07-11
PCT/US2013/049894 WO2014011750A1 (en) 2012-07-11 2013-07-10 Laquinimod formulations without alkalizing agent

Publications (1)

Publication Number Publication Date
HK1209054A1 true HK1209054A1 (en) 2016-03-24

Family

ID=49914501

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15109818.4A HK1209054A1 (en) 2012-07-11 2015-10-08 Laquinimod formulations without alkalizing agent

Country Status (19)

Country Link
US (1) US20140018386A1 (xx)
EP (1) EP2872141A4 (xx)
JP (1) JP2015527321A (xx)
KR (1) KR20150036553A (xx)
CN (1) CN104470519A (xx)
AR (1) AR091706A1 (xx)
AU (1) AU2013290274A1 (xx)
BR (1) BR112015000321A2 (xx)
CA (1) CA2873230A1 (xx)
EA (1) EA201590193A1 (xx)
HK (1) HK1209054A1 (xx)
IL (1) IL236229A0 (xx)
MX (1) MX2015000398A (xx)
NZ (1) NZ630241A (xx)
SG (2) SG11201407688QA (xx)
TW (1) TW201408299A (xx)
UA (1) UA115555C2 (xx)
WO (1) WO2014011750A1 (xx)
ZA (1) ZA201500287B (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009082471A1 (en) 2007-12-20 2009-07-02 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
JP2015505564A (ja) 2012-02-03 2015-02-23 テバ ファーマシューティカル インダストリーズ リミティド 第一選択の抗ＴＮＥα療法に失敗したクローン病患者を治療するためのラキニモドの使用
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
MX2015005632A (es) 2012-11-07 2016-02-05 Teva Pharma Sales de amina de laquinimod.
NZ630427A (en) 2013-03-14 2017-06-30 Teva Pharma Crystals of laquinimod sodium and improved process for the manufacture thereof
EP3137092A4 (en) 2014-04-29 2017-10-11 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
CN107823150A (zh) * 2017-10-25 2018-03-23 北京素维生物科技有限公司 一种可快速分散的片剂及其制备方法
CN107823168A (zh) * 2017-10-25 2018-03-23 北京素维生物科技有限公司 一种快速溶解的片剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
SE0400235D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
NZ567088A (en) * 2005-10-19 2012-06-29 Teva Pharma Crystals of laquinimod sodium, and process for the manufacture thereof
KR101495327B1 (ko) * 2006-06-12 2015-02-24 테바 파마슈티컬 인더스트리즈 리미티드 안정한 라퀴니모드 제제
WO2009082471A1 (en) * 2007-12-20 2009-07-02 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
WO2010070449A2 (en) * 2008-12-17 2010-06-24 Actavis Group Ptc Ehf Highly pure laquinimod or a pharmaceutically acceptable salt thereof
MX2014001048A (es) * 2011-07-28 2014-07-09 Teva Pharma Tratamiento de esclerosis multiple con combinacion de laquinimo de interferon-beta.

Also Published As

Publication number Publication date
EA201590193A1 (ru) 2015-04-30
BR112015000321A2 (pt) 2017-06-27
EP2872141A1 (en) 2015-05-20
SG11201407688QA (en) 2014-12-30
WO2014011750A1 (en) 2014-01-16
AU2013290274A1 (en) 2014-11-27
UA115555C2 (uk) 2017-11-27
MX2015000398A (es) 2015-04-10
AR091706A1 (es) 2015-02-25
TW201408299A (zh) 2014-03-01
NZ630241A (en) 2017-09-29
US20140018386A1 (en) 2014-01-16
KR20150036553A (ko) 2015-04-07
IL236229A0 (en) 2015-01-29
CA2873230A1 (en) 2014-01-16
CN104470519A (zh) 2015-03-25
ZA201500287B (en) 2016-10-26
JP2015527321A (ja) 2015-09-17
WO2014011750A8 (en) 2014-12-04
EP2872141A4 (en) 2016-01-13
SG10201700198VA (en) 2017-02-27

Similar Documents

Publication Publication Date Title
HK1212701A1 (zh) 恩雜魯胺製劑
TWI563077B (en) Cleaning formulations
HK1203812A1 (en) Novel pharmaceutical formulations
HK1209054A1 (en) Laquinimod formulations without alkalizing agent
HK1205679A1 (en) Nicotine formulation
PL2908835T3 (pl) Stabilne formulacje
IL234747A0 (en) Vascular formulations
HK1207290A1 (en) Oral formulation
IL235988B (en) Drug composition is based on genotype or phenotype
PL2908859T3 (pl) Formulacje arypiprazolu
HK1209339A1 (en) Pharmaceutical formulations
HK1202249A1 (en) Vesicular formulations
GB201211406D0 (en) Pharmaceutical formulations
GB201211403D0 (en) Pharmaceutical formulations
IL234771A0 (en) Nicotine formulation
GB201206178D0 (en) Formulations